Hefei Wen (
Jason M. Hockenberry is an associate professor in the Department of Health Policy and Management, Rollins School of Public Health, Emory University, in Atlanta, Georgia.
Health Aff (Millwood). 2019 Sep;38(9):1550-1556. doi: 10.1377/hlthaff.2019.00103.
Comprehensive mandates for prescription drug monitoring programs (PDMPs) require state-licensed prescribers and dispensers both to register with and to use the programs in most clinical circumstances. Such mandates have the potential to improve providers' participation and reduce opioid-related adverse events. Using Medicaid prescription data and hospital utilization data across the US in the period 2011-16, we found that state implementation of comprehensive PDMP mandates was associated with a reduction in the opioid prescription rate from 161.47 to 147.07 per 1,000 enrollees per quarter, a reduction in the opioid-related inpatient stay rate from 97.50 to 93.34 per 100,000 enrollees per quarter, and a reduction in the opioid-related emergency department (ED) visit rate from 74.60 to 61.36 per 100,000 enrollees per quarter. Our estimated annual reductions of approximately 12,000 inpatient stays and 39,000 ED visits could save over $155 million in Medicaid spending, a fact that deserves policy attention when states attempt to strengthen and refine PDMPs to better tackle the opioid crisis.
全面的处方药物监测计划(PDMP)授权要求州许可的开处方者和配药者在大多数临床情况下都要注册并使用该计划。此类授权有可能提高提供者的参与度并减少阿片类药物相关的不良事件。利用 2011-2016 年期间美国的医疗补助处方药数据和医院利用数据,我们发现,全面实施 PDMP 授权与以下方面相关:每季度每千名参保者的阿片类药物处方率从 161.47 降至 147.07,每季度每 10 万名参保者的阿片类药物相关住院率从 97.50 降至 93.34,以及每季度每 10 万名参保者的阿片类药物相关急诊就诊率从 74.60 降至 61.36。我们估计每年减少约 12000 次住院和 39000 次急诊就诊,这将节省超过 1.55 亿美元的医疗补助支出。当各州试图加强和完善 PDMP 以更好地应对阿片类药物危机时,这一事实值得政策关注。